Ubie, Inc., a Tokyo-based healthcare startup, has closed its Series C round at $45 million by raising $19 million in an extension round. The new funding will enable Ubie to accelerate its growth and strengthen its presence in the US, following strong interest and traction in that market. To date, Ubie has raised $76 million in total.

The extension round money was raised from SOGO MEDICAL CO., AAIC Investment, Japan Impact Investment II Limited Partnership, and Rakuten Capital, while loans extended from the Shoko Chukin Bank, Japan Finance Corporation, and Mizuho Bank.

Ubie, with the mission of "guiding people to appropriate medical care with technology," is one of the few companies in the world having direct contact with both patients and medical institutions. With artificial intelligence (AI) as its core technology, the company provides AI symptom checker Ubie as the gateway to medical care. It will also focus on expanding its business to the US in order to apply the technology it has developed in Japan, one of the leading countries in the medical field.

Leveraging the Series C funding, Ubie established a local subsidiary in New York. This is the second overseas corporation following Singapore. The decision follows the fact that the number of users has been increasing steadily since the release of the AI symptom checker in April 2022 in the US. The establishment of the local subsidiary will further strengthen the partnership with US pharmaceutical companies, as well as the products, including hiring local people in the US.